Pharmaceutical Technology on MSN15d
Eikon raises almost $351m to advance cancer candidates through the clinic
Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.
Medscape11d
Novel Drugs Targeting Toll-like Receptors for Antiviral Therapy
The TLR7 agonist imiquimod has been approved for the treatment of genital warts caused by HPV. TLR3 and TLR7–9 agonists showed promising results for the treatment of viral infections ...
Nature3y
Nanoparticle-stimulated neutrophils turn cold tumors hot
Its lead candidate, MBS8, consists of a small-molecule agonist of Toll-like receptor 7 (TLR7) in-licensed from the University of California San Diego, USA, and formulated by MonTa in collaboration ...
MedCity News16d
Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing
Eikon licensed global rights to that immunotherapy and another TLR7/8 agonist in 2023; financial terms were not disclosed. Choosing the right software translates directly into better client ...